From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2019 May 30

PMID 31137917

Citations 20

Authors

Philip Lazarovici

Cezary Marcinkiewicz

Peter I Lelkes

Affiliations

Soon will be listed here.

Abstract

Snake venoms are attractive natural sources for drug discovery and development, with a number of substances either in clinical use or in research and development. These drugs were developed based on RGD-containing snake venom disintegrins, which efficiently antagonize fibrinogen activation of αIIbβ3 integrin (glycoprotein GP IIb/IIIa). Typical examples of anti-platelet drugs found in clinics are Integrilin (Eptifibatide), a heptapeptide derived from Barbourin, a protein found in the venom of the American Southeastern pygmy rattlesnake and Aggrastat (Tirofiban), a small molecule based on the structure of Echistatin, and a protein found in the venom of the saw-scaled viper. Using a similar drug discovery approach, linear and cyclic peptides containing the sequence K(R)TS derived from VP12, a C-type lectin protein found in the venom of Israeli viper venom, were used as a template to synthesize Vipegitide, a novel peptidomimetic antagonist of α2β1 integrin, with anti-platelet activity. This review focus on drug discovery of these anti-platelet agents, their indications for clinical use in acute coronary syndromes and percutaneous coronary intervention based on several clinical trials, as well as their adverse effects.

Citing Articles

Emerging Trends in Snake Venom-Loaded Nanobiosystems for Advanced Medical Applications: A Comprehensive Overview.

Alves A, Barros A, Silva L, Carvalho L, Pereira G, Uchoa A Pharmaceutics. 2025; 17(2).

PMID: 40006571 PMC: 11858983. DOI: 10.3390/pharmaceutics17020204.

Snake venom bioprospecting as an approach to finding potential anti-glioblastoma molecules.

Orozco-Mera J, Montoya-Gomez A, Lopes D, Jimenez-Charris E J Venom Anim Toxins Incl Trop Dis. 2024; 30:e20240015.

PMID: 39285908 PMC: 11404105. DOI: 10.1590/1678-9199-JVATITD-2024-0015.

Analysis and Identification of Putative Novel Peptides Purified from Iranian Endemic Sochureki Snake Venom by MALDI-TOF Mass Spectrometry.

Nafiseh N, Hossein V, Nasser M, Mojtaba N, Minoo A, Mohammad Ali B Arch Razi Inst. 2024; 78(5):1503-1527.

PMID: 38590689 PMC: 10998951. DOI: 10.22092/ARI.2023.78.5.1503.

A Review of Rattlesnake Venoms.

Phan P, Deshwal A, McMahon T, Slikas M, Andrews E, Becker B Toxins (Basel). 2024; 16(1).

PMID: 38276526 PMC: 10818703. DOI: 10.3390/toxins16010002.

Snake Venom Components as Therapeutic Drugs in Ischemic Heart Disease.

Messadi E Biomolecules. 2023; 13(10).

PMID: 37892221 PMC: 10605524. DOI: 10.3390/biom13101539.

References

Marcinkiewicz C . Applications of snake venom components to modulate integrin activities in cell-matrix interactions. Int J Biochem Cell Biol. 2013; 45(9):1974-86. PMC: 3774133. DOI: 10.1016/j.biocel.2013.06.009. View

Derex L, Paris C, Nighoghossian N . Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update. J Am Heart Assoc. 2018; 7(2). PMC: 5850163. DOI: 10.1161/JAHA.117.007454. View

Gan Z, Gould R, Jacobs J, Friedman P, Polokoff M . Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem. 1988; 263(36):19827-32. View

Sanz L, Bazaa A, Marrakchi N, Perez A, Chenik M, Bel Lasfer Z . Molecular cloning of disintegrins from Cerastes vipera and Macrovipera lebetina transmediterranea venom gland cDNA libraries: insight into the evolution of the snake venom integrin-inhibition system. Biochem J. 2006; 395(2):385-92. PMC: 1422776. DOI: 10.1042/BJ20051678. View

Scarborough R, Rose J, Naughton M, Phillips D, Nannizzi L, Arfsten A . Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem. 1993; 268(2):1058-65. View

Barrett J, Murphy G, Peerlinck K, De Lepeleire I, Gould R, Panebianco D . Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994; 56(4):377-88. DOI: 10.1038/clpt.1994.152. View

Topol E, Moliterno D, Herrmann H, Powers E, Grines C, Cohen D . Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344(25):1888-94. DOI: 10.1056/NEJM200106213442502. View

Phillips D, Scarborough R . Clinical pharmacology of eptifibatide. Am J Cardiol. 1997; 80(4A):11B-20B. DOI: 10.1016/s0002-9149(97)00572-9. View

. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338(21):1488-97. DOI: 10.1056/NEJM199805213382102. View

10.

Swenson S, Ramu S, Markland F . Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des. 2007; 13(28):2860-71. DOI: 10.2174/138161207782023793. View

11.

Vickers S, Theoharides A, Arison B, Balani S, Cui D, Duncan C . In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos. 1999; 27(11):1360-6. View

12.

Marcinkiewicz C, Lobb R, Marcinkiewicz M, Daniel J, Smith J, Dangelmaier C . Isolation and characterization of EMS16, a C-lectin type protein from Echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry. 2000; 39(32):9859-67. DOI: 10.1021/bi000428a. View

13.

Lynch Jr J, COOK J, Sitko G, Holahan M, Ramjit D, Mellott M . Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther. 1995; 272(1):20-32. View

14.

Bennett J . Regulation of integrins in platelets. Biopolymers. 2015; 104(4):323-33. DOI: 10.1002/bip.22679. View

15.

Scarborough R, Rose J, Hsu M, Phillips D, Fried V, Campbell A . Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991; 266(15):9359-62. View

16.

Brown M, Eble J, Calvete J, Marcinkiewicz C . Structural requirements of KTS-disintegrins for inhibition of alpha(1)beta(1) integrin. Biochem J. 2008; 417(1):95-101. DOI: 10.1042/BJ20081403. View

17.

Scarborough R, Naughton M, Teng W, Rose J, Phillips D, Nannizzi L . Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993; 268(2):1066-73. View

18.

Arruda Macedo J, Fox J, Castro M . Disintegrins from snake venoms and their applications in cancer research and therapy. Curr Protein Pept Sci. 2015; 16(6):532-48. PMC: 4997955. DOI: 10.2174/1389203716666150515125002. View

19.

Rath D, Schaeffeler E, Winter S, Levertov S, Muller K, Droppa M . GPla Polymorphisms Are Associated with Outcomes in Patients at High Cardiovascular Risk. Front Cardiovasc Med. 2017; 4:52. PMC: 5566565. DOI: 10.3389/fcvm.2017.00052. View

20.

. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of.... Circulation. 1997; 96(5):1445-53. DOI: 10.1161/01.cir.96.5.1445. View